Altman Says OpenAI May Back Firms Using AI for Drug Discovery

OpenAI Chief Executive Officer Sam Altman said his company may consider investing in or subsidizing firms that make significant use of its AI technologies to discover new drugs or therapies, and possibly take a royalty in exchange

The AI developer could choose to cover the cost of using its artificial intelligence models in partnership with a drug company and then “get some royalty” from discoveries made by that firm, Altman said at Cisco Systems Inc.’s AI conference in San Francisco on Tuesday. The ChatGPT maker has no such partnerships at present, he said.

“This is not something we’re doing ...